Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 197

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 197
---
632

    89,673

    271,959

    Change in fair value of derivative liability

    (313,772
    )

    -

    (313,772
    )

    Total other income (expense)

    (4,032,814
    )

    447,894

    (4,146,265
    )

    Net loss
     
    $
    (21,682,306
    )
     
    $
    (29,316,826
    )
     
    $
    7,968,963

    Series A Preferred cash dividend

    (2,089
    )

    -

    (2,089
    )

    Warrant modification

    (965,177
    )

    -

    (965,177
    )

    Net loss attributable to common shareholders
     
    $
    (22,649,572
    )
     
    $
    (29,316,826
    )
     
    $
    6,667,254

Research and Development Expenses. The following table summarizes our research and development expenses by program for the periods presented.

    Year ended

    December 31,

    Change

    2024

    2023

    (in thousands)

    Direct program costs:

    IFx-2.0
     
    $
    7,286,319

    $
    5,679,869

    $
    1,606,450

    Preclinical research costs

    702,628

    316,178

    386,450

    Indirect program costs:

    Personnel and facilities related costs

    5,346,370

    3,406,370

    1,940,000

    Total research and development expenses
     
    $
    13,335,316

    $
    9,402,417

    $
    3,932,899

Research and development expenses were $13.3 million and $9.4 million for the years ended December 31, 2024, and 2023, respectively. The increase of $3.9 million related to the following.

•an increase of approximately $1.6 million due to ongoing clinical development of IFx-2.0;

•an increase of approximately $0.4 million due to preclinical research of IFx-3.0 and MDSCs; and

•an increase of approximately